Clinical Trial Update: CDIAG Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for the CDIAG regimen in relapsed or refractory acute myeloid leukemia has completed enrollment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• CDIAG regimen

Snippet

Sponsor: The First Affiliated Hospital of Soochow University | Conditions: Acute Myeloid Leukemia, Relapsed, Adult | Phase 2 | Status: COMPLETED